Skeletal Muscle Mass Change During Chemotherapy: A Systematic Review and Meta-analysis

Skeletal muscle mass loss is an emerging concern in oncology. Our systematic review and meta-analysis identified the mean difference in skeletal muscle index pre- to post-chemotherapy and synthesized potential key factors. We searched primary original research published through October 2019 in four...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Anticancer research Ročník 40; číslo 5; s. 2409 - 2418
Hlavní autoři: JANG, MIN KYEONG, PARK, CHANG, HONG, SUSAN, LI, HONGJIN, RHEE, ESTHER, DOORENBOS, ARDITH Z.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Greece International Institute of Anticancer Research 01.05.2020
Témata:
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer therapies
Chemotherapy
Females
Gastric cancer
Handbooks
Humans
Lung cancer
Medical prognosis
Medical Subject Headings-MeSH
Meta-analysis
Mortality
Muscle, Skeletal - pathology
Muscles
Musculoskeletal system
Neoplasms - complications
Neoplasms - drug therapy
Non-small cell lung carcinoma
Oncology
Organ Size
Sarcopenia
Sarcopenia - etiology
Sarcopenia - pathology
Skeletal muscle
Small cell lung carcinoma
Systematic review
Toxicity
meta-analysis
cancer
Muscle mass loss
skeletal muscle index
review
sarcopenia
ISSN:0250-7005, 1791-7530, 1791-7530
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Skeletal muscle mass loss is an emerging concern in oncology. Our systematic review and meta-analysis identified the mean difference in skeletal muscle index pre- to post-chemotherapy and synthesized potential key factors. We searched primary original research published through October 2019 in four databases: MEDLINE via PubMed, Scopus, CINAHL, and Embase. Fifteen studies were included, 60% published in the past 2 years (2018-2019). Advanced non-small cell lung cancer was the most frequently reported cancer, and overall survival the most often identified key related factor. Mean difference in skeletal muscle index during chemotherapy was 2.72 (95%CI=1.77-3.67, p=0.00), with muscle loss in males (4.52, 95%CI=3.34-5.71, p=0.00) about 1.6 times higher than that in females (2.86, 95%CI=0.81-4.92, p=0.01). Oncologists should recognize sex-specific differences in skeletal muscle mass loss during chemotherapy and consider adjusting treatment accordingly.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ObjectType-Undefined-4
ISSN:0250-7005
1791-7530
1791-7530
DOI:10.21873/anticanres.14210